Lumexa Imaging initiated with an Outperform at Leerink

Leerink initiated coverage of Lumexa Imaging (LMRI) with an Outperform rating and $23 price target The firm says Lumexa possesses many powerful secular growth themes anchored to evolving technology, growth and a favorable shift in advanced imaging, low-cost outpatient care, and demographic tailwinds. Leerink forecasts a 30% increase in new imaging centers by 2030 which elevates the case for accelerating organic growth. The company’s unique and aspirational JV model aligns strongly with health system ambulatory priorities, the firm adds. Leerink believes Lumexa carries the potential to be a double-digit compounding EBITDA grower over time.